<DOC>
	<DOCNO>NCT01268683</DOCNO>
	<brief_summary>The study objective ass feasibility enrolling , evaluate , treat RP-1127 ( Glyburide Injection ) severe anterior circulation ischemic stroke patient , whether treat standard care IV rtPA . Patients must 18-80 year age , must baseline diffusion weight image ( DWI ) lesion volume 82 - 210 cm3 , time symptom onset start study infusion must ≤10 hr .</brief_summary>
	<brief_title>Glyburide Advantage Malignant Edema Stroke Pilot</brief_title>
	<detailed_description>This multi-center , prospective , open label , Phase IIa trial RP-1127 ( Glyburide Injection ) 10 patient severe anterior circulation ischemic stroke likely experience clinically significant brain swelling . Subjects receive RP-1127 ( Glyburide Injection ) , deliver IV bolus follow IV infusion 72 hour . Subjects baseline ( pretreatment ) MRI scan standard care , three follow MRI scan ( 24+12 hour , 48+12 hour , 72±12 hour ) . Since recanalization may effect outcome , result vascular study , obtain part standard care define CTA , MRA catheter angiography head neck , record . Additionally , clinical endpoint NIHSS , GCS FOUR Score ( baseline , 24±12 hour , 48±12 hour , 72±12 hour 7±1 day ) mRS ( 30±5 day 90±7 day ) assess . Safety parameter assess Day 7 discharge ( whichever sooner ) , Day 30±5 Day 90±7 . Study participation expect last 90±7 day .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>A clinical diagnosis acute ischemic stroke MCA MCA/ACA territory . Premorbid mRS 0 1 . A baseline DWI lesion 82 cm3 210 cm3 MRI . Patients treat IV rtPA meet establish criterion IV rtPA administration 03 34.5 hr time period , respectively . The time start infusion study compound must ≤ 10 hr time symptom onset Age ≥18 year ≤70 year . Provision write informed consent patient legally authorize representative accord institutional guideline national regulation . Evidence image preenrollment investigation diagnosis acute ischemic stroke likely cause present symptom sign . Commitment decompressive craniectomy ( DC ) prior enrollment , follow enrollment prior start study compound . Treatment IA rtPA mechanical mean clot disruption hypothermia . Patients unable tolerate MRI scanning , e.g . pacemaker automatic defibrillator . Premorbid mRS ≥ 2 . Clinical sign herniation , e.g . one two dilate , fix pupil ; unconsciousness ( i.e. , ≥ 2 item 1a NIHSS ) ; loss brain stem reflex attributable herniation accord investigator 's judgment . CT MRI evidence hemorrhage anteroseptal/pineal shift great ≥2 mm prior enrollment . Rapidly improve symptom . Severe renal disorder patient 's history ( e.g . dialysis ) eGFR &lt; 30 mL/min/1.73 m2 . Severe liver disease ALT , AST , bilirubin &gt; 2 time normal . Blood glucose &lt; 55 mg/dL enrollment immediately prior administration RP1127 , clinically significant history hypoglycemia . Diagnosis decompensated heart failure ( e.g . clinical diagnosis pulmonary edema , chest xray consistent heart failure , tachypnea &gt; 20 , etc . ) Sulfonylurea treatment within 30 day . Known allergy sulfa specific allergy sulfonylurea drug . Known G6PD enzyme deficiency . Pregnancy breastfeed . Women must either postmenopausal ( judged investigator ) , permanently sterilize , childbearing age , must negative test pregnancy obtain enrollment . Patients already enrol nonobservationonly stroke study , lifeexpectancy &lt; 3 month relate current stroke , unlikely compliant follow . Patients , opinion investigator , suitable study ( reason document ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Ischemic stroke</keyword>
</DOC>